sponsored
PatientsVille.com Logo

PatientsVille

Dialysis Medical Research Studies

Up-to-date List of Dialysis Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Dialysis Medical Research Studies

Rank Status Study
1 Not yet recruiting Adjuvant Peritoneal Dialysis on a Background of Thrice-Weekly HemoDialysis
Conditions: Functionally Anuric;   HemoDialysis/Peritoneal Dialysis
Intervention: Other: Adjuvant Peritoneal Dialysis in the context of ongoing HemoDialysis
Outcome Measures: Frequency of adverse events;   baseline-to-follow up changes in inter-HD weight gain;   baseline-to-follow up changes in HD dry weight (lowest tolerated at each time point);   baseline-to-follow up changes in ambulatory blood pressures;   baseline-to-follow up changes in pre-HD serum phosphorus;   baseline-to-follow up changes in pre-to-post HD changes in serum potassium and total carbon dioxide (CO2);   baseline-to-follow up changes in Kidney Disease Quality of Life Short Form (KDQoL-SF) scores for physical functioning, energy fatigue, and general health
2 Unknown  Blood Pressure in Dialysis Patients
Conditions: Hypertension;   Renal Failure Chronic Requiring HemoDialysis;   Fluid Overload
Interventions: Drug: Antihypertensive Agents;   Other: Dry weight Challenge;   Dietary Supplement: Extend Dialysis treatment time and re-challenge estimated dry weight
Outcome Measures: Feasibility and safety of randomizing patients to a low (110-140 mm Hg) and standard (155-165 m Hg)pre-Dialysis BP Goal;   Change in LV mass;   Health-related quality of life;   Residual Renal Function;   Feasibility of Performing Standardized Dialysis Unit BP Readings;   Feasibility of home BP monitoring;   Feasibility of ambulatory BP monitoring
3 Not yet recruiting Virtual Ward for Home Dialysis
Conditions: End Stage Renal Disease;   Kidney Failure;   Home Dialysis
Interventions: Other: Telephone follow-up;   Other: Sympton Assessment
Outcome Measures: The number of care gaps identified.;   Dialysis prescription and adherence.;   Morbidity associated with Dialysis therapy.;   Burden associated with travel time for patients.;   Medication reconciliation.;   Symptom management.;   Adherence with dietary recommendations.;   Coordination of care among participating providers.;   Patient satisfaction.
4 Recruiting Comparison of Quality of Life on Automated Peritoneal Dialysis and Continuous Ambulatory Peritoneal Dialysis
Conditions: End Stage Renal Disease;   Peritoneal Dialysis
Intervention:
Outcome Measure: Change in Quality of Life
5 Recruiting Clinical Evaluation of Low Sodium Peritoneal Dialysis (PD) Solution on Hypertensive Patients Treated With PD
Condition: Chronic Kidney Failure
Intervention: Drug: Solution for Peritoneal Dialysis
Outcome Measures: The primary criterion is the ambulatory 24 h mean systolic blood pressure measurement and drug doses management after 2 months of treatment compared to Baseline.;   Measurement of Residual Renal Function;   Follow-up of frequency of hyponatremia, of AE and SAE;   Assessment of changes in sodium removal;   Assessment of decrease in total body water (extra and intra cellular water)and of the body weigh changes;   Measurement of 24hours peritoneal clearance;   Office systolic and diastolic blood pressure measurement at month 2 and 6 versus T0;   Office systolic and diastolic blood pressure measurement during follow up period
6 Unknown  Decreasing Dialysis Cardiovascular Risk: Daily Versus Longer Treatments
Condition: Cardiovascular Disease
Intervention: Procedure: Dialysis
Outcome Measure: LVM change per Cardiac MRI
7 Unknown  Web-based Interactive Health Communication Application (IHCA) for Successful Home Dialysis
Condition: Chronic Kidney Disease
Interventions: Behavioral: Interactive Health Communication Application;   Behavioral: No Intervention: Usual Care
Outcome Measures: Number of patients that start home-based Dialysis.;   Number intended to start home-based Dialysis;   Increase in Dialysis knowledge;   Increase in decision making and social support.;   Mortality differences
8 Not yet recruiting Effectiveness of an Online Portal for Delivery of Care to Home Dialysis Patients
Conditions: HemoDialysis, Home;   Peritoneal Dialysis
Intervention: Other: Electronic Patient Portal
Outcome Measures: Change in Quality of Life;   Change in Patient Satisfaction;   Hospitalization and Health-Care Utilization Rates;   Dialysis Self-Efficacy
9 Recruiting Sympathetic Activity in Patients With End-stage Renal Disease on Peritoneal Dialysis
Conditions: End-stage Renal Disease (ESRD);   Kidney Disease
Interventions: Other: DIANEAL;   Other: EXTRANEAL
Outcome Measures: Changes in muscle sympathetic nerve activity(MSNA);   Changes in leptin levels;   Changes in blood pressure as assessed from 24-hour ambulatory blood pressure monitor (ABPM);   Changes in extracellular volume assessed by bioelectrical impedance (BIA);   Changes in heart rate variability;   Changes in central intravascular volume assessed by cardiac ultrasound;   Changes in plasma catecholamines levels;   Changes in BNP (Brain Natriuretic Peptide)levels;   Changes in plasma insulin levels
10 Unknown  Effect of Different Dialysis Dosage on Prognosis in Maintenance Peritoneal Dialysis Patients
Condition: End-Stage Renal Disease
Interventions: Drug: 6 L dialysate;   Drug: 8 L dialysate
Outcome Measures: clinical outcome including mortality and technical failure;   complications including cardiovascular disease, nutritional and inflammation status, calcium and phosphorus level, anemia and life quality
11 Recruiting Diurnal Variation of Mineral Metabolism and Protein Fermentation Metabolites in Peritoneal Dialysis Patients and Healthy Volunteers
Condition: Peritoneal Dialysis
Intervention:
Outcome Measure: To evaluate the diurnal variation of serum concentrations of phosphate and protein fermentation metabolites in healthy volunteers as compared to Dialysis patients.
12 Recruiting Prevention of Peritonitis in Peritoneal Dialysis
Conditions: Kidney Failure, Chronic;   Peritoneal Dialysis-associated Peritonitis;   Dialysis Capd Infection
Intervention: Behavioral: Follow-up of PD patients´ theoretical and practical skills
Outcome Measures: Peritonitis-free survival at 12 months after PD start;   Incidence of peritonitis;   Risk factors for peritonitis;   Days of hospitalization due to peritonitis
13 Not yet recruiting Peritonitis and Loss of Residual Renal Function, Technique Failure and Mortality in Peritoneal Dialysis Patients
Conditions: Loss of Residual Renal Function;   Technique Failure in Peritoneal Dialysis
Intervention:
Outcome Measures: Loss of residual renal function;   Technique (peritoneal Dialysis) failure
14 Unknown  Anti-Oxidant Effect on Peritoneal Membrane in Peritoneal Dialysis (PD) Patients
Conditions: End-Stage Kidney Disease;   Peritoneal Dialysis
Intervention: Drug: N-acetylcysteine
Outcome Measures: Peritoneal membrane function;   Oxydative stress status;   Mesothelial cell transformation (Epithelial to Mesenchymal Transition);   Residual renal function
15 Recruiting Bacteria Endotoxin in Peritoneal Dialysis Effluent as a Predictor of Relapsing, Recurrent, and Repeat Peritonitis
Condition: Peritoneal Dialysis Associated Peritonitis
Intervention: Other: endotoxin assay in peritoneal Dialysis effluent
Outcome Measures: relapsing peritonitis;   recurrent peritonitis;   repeat peritonitis;   conversion to long-term hemoDialysis;   peritonitis that requires hospitalization;   catheter removal;   death due to peritonitis;   all cause mortality
16 Recruiting Conventional HemoDialysis Vs Short Daily HemoDialysis for Patients Coming From Home Automated Peritoneal Dialysis
Condition: End Stage Renal Disease
Interventions: Procedure: Short daily hemoDialysis;   Procedure: Conventional hemoDialysis
Outcome Measures: mean quality-adjusted life year (QALY) score in the first year after the start of Dialysis;   Dialysis related cost of care;   transportation costs per patient per year for the journeys "home-hospital-home";   transportation costs per patient per year for the journeys "home-hospital-home;   ratio nurse/patients;   hospitalization rate (admissions and days;   weekly standardized Kt/V delivered;   systolic blood pressure and use of antihypertensive medications;   mineral metabolism, anemia parameters and nutritional parameters;   maintenance of residual renal function
17 Not yet recruiting Study to Evaluate the Efficacy and Safety of Oxabact (OC5) in Primary Hyperoxaluria Patients Who Are on Dialysis
Condition: Primary Hyperoxaluria
Intervention: Biological: Oxalobacter formigenes
Outcome Measures: Change in pre Dialysis plasma oxalate level after 6 weeks of treatment, compared with baseline.;   Change in pre-Dialysis plasma oxalate levels during 6 weeks of treatment in subsets of subjects defined by Dialysis regimen (HD or PD).;   Duration of efficacy measured by pre Dialysis plasma oxalate values from week 10 to week 14, following termination of OC5 treatment.;   Change in number of O. formigenes in faeces during 6 weeks of treatment.;   Change in total oxalate removal by Dialysis and urinary clearance during 6 weeks of treatment in a limited number of subjects participating in the sub-study.;   Adverse events (AEs);   Hematology;   Clinical chemistry;   Urinalysis
18 Recruiting An Evaluation of a Cytomegalovirus (CMV) Vaccine (ASP0113) in CMV-Seropositive and CMV-Seronegative Healthy Subjects and CMV-Seronegative Dialysis Patients
Conditions: Healthy Subjects;   Cytomegalovirus Infection;   Dialysis
Interventions: Drug: ASP0113;   Drug: Placebo
Outcome Measures: ASP0113 plasmids pharmacokinetics in plasma: AUC (Part 1 and Part 2);   ASP0113 plasmids pharmacokinetics in plasma: Cmax (Part 1 and Part 2);   ASP0113 plasmids pharmacokinetics in plasma: Tmax (Part 1 and Part 2);   ASP0113 plasmids pharmacokinetics in plasma: Apparent clearance (Part 1 and Part 2);   ASP0113 plasmids pharmacokinetics in plasma: apparent volume of distribution (Part 1 and Part 2);   ASP0113 plasmids pharmacokinetics in plasma: half-life (Part 1 and Part 2);   pp65 protein in white blood cells (WBCs) using pp65 antigenemia assay (Part 1 and Part 2);   Immunogenicity: Relative units/ml of anti-gB antibodies in serum as detected by enzyme-linked immunosorbent assay (ELISA) (Part 2);   Immunogenicity: Number of pp65-specific Interferon (IFN)-gamma producing T-cells in isolated peripheral blood mononuclear cells (PBMCs) upon pp65 peptide stimulation as assayed by flow cytometry with intracellular cytokine staining (ICS) (Part 2);   Immunogenicity: Amount of IFN-gamma produced by CMV peptide-stimulated T-cells in whole blood using the QuantiFERON T-cell CMV assay (Part 2);   Safety assessed by clinical labs, vital signs, and adverse events including local and systemic reactogenicity
19 Recruiting A Study of The Effect of Altitude on Mircera (Methoxy Polyethylene Glycol-Epoetin Beta) Dose Requirements in Patients With Chronic Renal Anemia in Pre-Dialysis or Dialysis
Condition: Anemia, Kidney Disease, Chronic
Intervention: Drug: methoxy polyethylene glycol-epoetin beta [Mircera]
Outcome Measures: Dosage required to achieve target haemoglobin concentration of 11-12 g/dL;   Change in haemoglobin concentration;   Percentage of patients achieving target haemoglobin concentration 11-12 g/dL after 3 and 6 months of treatment;   Safety: Incidence of adverse events;   Proportion of patients requiring dose adjustments;   Incidence of red blood cell transfusions
20 Unknown  Barriers to Peritoneal Dialysis Selection
Condition: Chronic Kidney Disease
Intervention:
Outcome Measure: Barriers to making a Dialysis modality decision

These studies may lead to new treatments and are adding insight into Dialysis etiology and treatment.

A major focus of Dialysis research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.


Discuss Dialysis